vs
ICU MEDICAL INC（ICUI）与BOSTON BEER CO INC（SAM）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是BOSTON BEER CO INC的1.2倍（$540.7M vs $461.6M），BOSTON BEER CO INC同比增速更快（-4.1% vs -14.1%），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -10.7%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
波士顿啤酒公司是美国知名酿酒企业，1984年由吉姆·科赫与朗达·卡尔曼联合创立。旗下首款产品以美国开国元勋、独立运动先驱塞缪尔·亚当斯命名，后续陆续推出多个自有品牌，2019年正式完成与角鲨头酿酒厂的合并，是北美精酿啤酒行业的核心参与者之一。
ICUI vs SAM — 直观对比
营收规模更大
ICUI
是对方的1.2倍
$461.6M
营收增速更快
SAM
高出10.0%
-14.1%
两年增速更快
ICUI
近两年复合增速
-10.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $461.6M |
| 净利润 | $-15.7M | — |
| 毛利率 | 37.5% | 46.4% |
| 营业利润率 | 1.0% | 12.4% |
| 净利率 | -2.9% | — |
| 营收同比 | -14.1% | -4.1% |
| 净利润同比 | 34.0% | — |
| 每股收益（稀释后） | $-0.63 | $2.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUISAM
| Q1 26 | — | $461.6M | ||
| Q4 25 | $540.7M | $385.7M | ||
| Q3 25 | $537.0M | $537.5M | ||
| Q2 25 | $548.9M | $587.9M | ||
| Q1 25 | $604.7M | $453.9M | ||
| Q4 24 | $629.8M | $402.3M | ||
| Q3 24 | $589.1M | $605.5M | ||
| Q2 24 | $596.5M | $579.1M |
净利润ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | $-15.7M | $-22.5M | ||
| Q3 25 | $-3.4M | $46.2M | ||
| Q2 25 | $35.3M | $60.4M | ||
| Q1 25 | $-15.5M | $24.4M | ||
| Q4 24 | $-23.8M | $-38.8M | ||
| Q3 24 | $-33.0M | $33.5M | ||
| Q2 24 | $-21.4M | $52.3M |
毛利率ICUISAM
| Q1 26 | — | 46.4% | ||
| Q4 25 | 37.5% | 43.5% | ||
| Q3 25 | 37.4% | 50.8% | ||
| Q2 25 | 37.9% | 49.8% | ||
| Q1 25 | 34.7% | 48.3% | ||
| Q4 24 | 36.1% | 39.9% | ||
| Q3 24 | 34.8% | 46.3% | ||
| Q2 24 | 34.8% | 46.0% |
营业利润率ICUISAM
| Q1 26 | — | 12.4% | ||
| Q4 25 | 1.0% | -8.6% | ||
| Q3 25 | 2.6% | 11.5% | ||
| Q2 25 | 1.9% | 14.0% | ||
| Q1 25 | 2.1% | 7.4% | ||
| Q4 24 | 6.0% | -13.9% | ||
| Q3 24 | 1.4% | 7.6% | ||
| Q2 24 | 1.3% | 12.2% |
净利率ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | -5.8% | ||
| Q3 25 | -0.6% | 8.6% | ||
| Q2 25 | 6.4% | 10.3% | ||
| Q1 25 | -2.6% | 5.4% | ||
| Q4 24 | -3.8% | -9.6% | ||
| Q3 24 | -5.6% | 5.5% | ||
| Q2 24 | -3.6% | 9.0% |
每股收益（稀释后）ICUISAM
| Q1 26 | — | $2.16 | ||
| Q4 25 | $-0.63 | $-1.97 | ||
| Q3 25 | $-0.14 | $4.25 | ||
| Q2 25 | $1.43 | $5.45 | ||
| Q1 25 | $-0.63 | $2.16 | ||
| Q4 24 | $-0.97 | $-3.23 | ||
| Q3 24 | $-1.35 | $2.86 | ||
| Q2 24 | $-0.88 | $4.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $164.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $682.6M |
| 总资产 | $4.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUISAM
| Q1 26 | — | $164.1M | ||
| Q4 25 | — | $223.4M | ||
| Q3 25 | — | $250.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $152.5M | ||
| Q4 24 | $308.6M | $211.8M | ||
| Q3 24 | $312.5M | $255.6M | ||
| Q2 24 | $302.6M | $219.3M |
股东权益ICUISAM
| Q1 26 | — | $682.6M | ||
| Q4 25 | $2.1B | $846.3M | ||
| Q3 25 | $2.1B | $911.0M | ||
| Q2 25 | $2.1B | $912.3M | ||
| Q1 25 | $2.0B | $897.0M | ||
| Q4 24 | $2.0B | $916.2M | ||
| Q3 24 | $2.0B | $1.0B | ||
| Q2 24 | $2.0B | $1.0B |
总资产ICUISAM
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.1B | $1.2B | ||
| Q3 25 | $4.1B | $1.2B | ||
| Q2 25 | $4.1B | $1.3B | ||
| Q1 25 | $4.2B | $1.2B | ||
| Q4 24 | $4.2B | $1.3B | ||
| Q3 24 | $4.3B | $1.4B | ||
| Q2 24 | $4.3B | $1.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | $39.9M | ||
| Q3 25 | $56.7M | $101.8M | ||
| Q2 25 | $11.2M | $126.5M | ||
| Q1 25 | $51.3M | $1.9M | ||
| Q4 24 | $40.2M | $41.9M | ||
| Q3 24 | $36.1M | $115.9M | ||
| Q2 24 | $82.0M | $96.0M |
自由现金流ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | $22.1M | ||
| Q3 25 | $27.6M | $89.2M | ||
| Q2 25 | $-8.5M | $112.2M | ||
| Q1 25 | $36.7M | $-8.0M | ||
| Q4 24 | $16.1M | $18.4M | ||
| Q3 24 | $16.2M | $99.2M | ||
| Q2 24 | $62.5M | $75.6M |
自由现金流率ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 5.7% | ||
| Q3 25 | 5.1% | 16.6% | ||
| Q2 25 | -1.5% | 19.1% | ||
| Q1 25 | 6.1% | -1.8% | ||
| Q4 24 | 2.6% | 4.6% | ||
| Q3 24 | 2.7% | 16.4% | ||
| Q2 24 | 10.5% | 13.1% |
资本支出强度ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 4.6% | ||
| Q3 25 | 5.4% | 2.3% | ||
| Q2 25 | 3.6% | 2.4% | ||
| Q1 25 | 2.4% | 2.2% | ||
| Q4 24 | 3.8% | 5.8% | ||
| Q3 24 | 3.4% | 2.8% | ||
| Q2 24 | 3.3% | 3.5% |
现金转化率ICUISAM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.21× | ||
| Q2 25 | 0.32× | 2.09× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.46× | ||
| Q2 24 | — | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
SAM
暂无分部数据
